Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Best practice guidelines

Vaccine hesitancy in Maltese family physicians and their trainees vis-à-vis influenza and novel COVID-19 vaccination

INTRODUCTION

An effective vaccine may help us to exit the COVID-19 pandemic. General Practitioners/Family Doctors (GPs/FDs) play a vital role in public vaccination in most countries and they also serve as role models. However, they may not always follow national vaccination policies. This study was carried out in order to ascertain the degree of vaccine hesitancy of GPs and GP trainees in Malta vis-à-vis influenza vaccination and a putative novel COVID-19 vaccine.

METHODS: A short, anonymous questionnaire was emailed via the Malta College of Family Doctors.

RESULTS: There were 123 responses from 288 GPs (33.3%) and 62 trainees (43.5%). Significantly more will take the influenza vaccine, at all ages. Almost two thirds of GPs are likely to take the COVID-19 vaccine but significantly less (a third) of trainees will. Older doctors were likelier to take this vaccine. The likelihood of taking influenza vaccination was significantly associated with that of taking COVID-19 vaccine. The majority of COVID-19 concerns pertained to insufficient knowledge and concern regarding potential long-term side effects.

DISCUSSION: The vaccination rates for COVID-19 are somewhat less than those for influenza uptake. Vaccine hesitancy in the young, and here in young doctors, is a seemingly global youth phenomenon, an unwise insouciance when the possibility of long-term viral complications is considered. An information drive should be mounted with regard to COVID-19 vaccination as well as a campaign to heavily promote annual influenza vaccination.

1. Introduction

While COVID-19 stalks the world, abated only by non-pharmaceutical interventions, the only real hope of controlling this pandemic is an effective vaccine. However, vaccine hesitancy is rampant [1], fuelled and abetted by social media [2], such that for what should be a highly anticipated and avidly sought COVID-19 vaccine, hesitancy ranges from 2 to 6% in China to 43% in the Czech Republic and 44% in Turkey by the general public [3].

General Practitioners/Family Doctors (GPs/FDs) play a vital role in public vaccination in most countries, and they also serve as role models in their own health behaviours [4]. In many countries, they are also the most utilised and trusted sources of information on this topic [5].

The most commonly reported motives for GP’s own vaccination are to protect themselves and their patients, while the commonest reasons for vaccine hesitancy include preference for actual exposure to disease thereby providing natural immunological protection, concerns regarding side effects, forgetfulness and their own personal doubts about vaccine efficacy [4].

With regard to vaccinating target patients, it is not unknown for GPs not to recommend nationally recommended vaccines. For example, a recent French study showed that 16%–43% of GPs sometimes/never recommended ≥1 vaccine/s to their target patients. The authors also noted that vaccines were more frequently recommended when GPs were comfortable explaining vaccine benefits and risks and trusted their official sources of vaccine information. On the other hand they failed to recommend vaccination when they felt that the risks of adverse effects were high or doubted the vaccine’s effectiveness [6]. In Malta both the public and the medical profession are much more compliant with vaccination schedules, with vaccination rates >90% [7].

This study was carried out in order to ascertain the degree of vaccine hesitancy of GPs and GP trainees in Malta vis-à-vis influenza vaccination and a putative novel COVID-19 vaccine that should be available in Malta later this year.

2. Methods

A short, anonymous questionnaire was sent out via the email mailing list of the Malta College of Family Doctors. This list comprises the email addresses of the membership roll. The mailshot was also sent to the current cohort of GP Trainees. The first mail was sent on 25/09/20 and a reminder was sent on 27/09/20. The questionnaire was available from 25/09/2020 to 29/09/2020. The questionnaire was hosted via Google forms and exported to bespoke Excel spreadsheets for analysis. It commenced with the following introduction:

Malta has been fortunate to have EARLY allocation of a COVID-19
vaccine later this year. The vaccine will be one that is licensed and approved and will have passed through Phase 3 trials. Priority will be given to front liners and to the vulnerable, followed later by the rest of the population. This is totally anonymous and a very short, public health survey for healthcare workers, please fill completely.

The questions, formatted in tick boxes, covered demographic details including sex, role (GP/GP trainee), age bracket, whether the influenza vaccine was taken last winter and whether it would be taken this coming winter (yes/no). The following text was inserted in the questionnaire followed by several questions with a Likert scale of 1–5.

QUICK READ FOR INFORMATION: Vaccine development is a three-phase process. In Phase I, small groups of people receive the trial vaccine. In Phase II, the vaccine is given to people who have characteristics (such as age and physical health) similar to those for whom the vaccine is intended. In Phase III, the vaccine is given to thousands of people and checked for efficacy and safety. The COVID vaccine that will arrive in Malta will have gone through these Phases and will be approved and licensed.

Based on this information, how likely are you to take the COVID-19 vaccine?

I am concerned as I don’t know enough about the vaccine.

I am concerned about safety (e.g. fever etc.).

I am concerned about possible long term side effects.

I am concerned as I don’t think the vaccine will be effective.

I am against vaccines in general.

For the first question in the list above, it was assumed that scores 1 and 2 were “unlikely”, 4 and 5 were “likely” and a score of 3 was taken as undecided. For the Likert questions following the first, all were allowed to tick options whatever their likelihood of taking the vaccine was. Chi tests and Chi tests for trend were used except for one two by two table with small values wherein a Fischer exact test was used. A p value ≤0.05 was taken to represent a statistically significant result.

3. Results

3.1. Influenza

There were 123 responses from 288 GPs (33.3%) and 62 trainees (43.5%). Table 1 shows the percentage of participants who took the influenza vaccine last year, and those who will be taking it this year, by role. More will be taking the vaccine, with this being a significant increase in the GP cohort. The projected increase in vaccination rate is significant at almost all ages (Table 2).

3.2. COVID-19

Table 1 shows the percentages who are likely to take the COVID-19 vaccine. Almost two thirds of GPs are likely to take it but less than a third of trainees will. This was a significant difference (chi 23.5, p < 0.0001) that was also reflected in the proportion likely to take this vaccine by age, with increasing age a significant predictor of vaccine uptake (chi = 8.5, p = 0.003). Males were more likely to take the vaccine than females (70% vs 54%) but this was not statistically significant.

The likelihood of taking the influenza vaccine was associated with the likelihood of taking the COVID-19 vaccine (chi = 28.5, p < 0.0001, Table 3). The majority of COVID-19 vaccine related concerns pertained to insufficiency knowledge with regard to this novel inoculation and concern with regard to potential long-term side effects. (See Table 4.)

4. Discussion

The projected increased influenza vaccine uptake is probably related to increased awareness of respiratory disease due to COVID-19 and the very recent study which indicated that contracting influenza with COVID-19 may double the risk of death [8]. The limitations of this study were the small numbers involved (n = 58), but 43% of those with both infections died, compared with 26.9% of those who only had COVID-19 with the greatest risk being to those aged over 65 [8].

In our study, the proportions are not as high as would be preferred and indeed, influenza vaccine uptake by healthcare workers in Malta is notoriously lower than wished for, but doctors do show a higher uptake than other healthcare workers. The rates described for GPs in this study are similar to influenza vaccine uptake by doctors in past years [9].

With regard to COVID-19 vaccination, younger doctors and trainees were less likely to take the inoculation. Indeed, in many countries, it has been noticed that young people are less concerned with COVID-19 than the adult and elderly population, possibly because of perceived milder symptoms in their age group and their lower risk of complications, an unsound insouciant attitude [10].

It could be argued that older individuals are at higher risk and therefore it is even more in their self-interest and in the interest of their family members to take the vaccine [11]. It is also possible that the younger and more social media active doctors are likelier to be influenced by vaccine hesitant narratives [12]. This scenario is reinforced by the finding that the likelihood of taking the influenza vaccine was associated with likelihood of taking the COVID-19 vaccine, indicating hesitancy toward both vaccines. The concerns with regard to insufficient knowledge are not invalid, however the country has been reassured that only vaccines that have passed through phase 3 trials will be purchased.

It has been estimated that COVID-19 herd immunity may be achieved at 55%–82% [13]. Since a non-trivial proportion of the population will be ineligible for COVID-19 vaccination by virtue of age, immunological status or other pre-existing medical conditions, any significant vaccine hesitancy will additionally hinder the attainment of this goal. Furthermore, given that a COVID-19 vaccine is unlikely to be 100% effective on all vaccinates, the population vaccinated should ideally approach totality.

With the onset of the COVID-19 pandemic, and the clear urgency for the discovery of an effective vaccine, many assumed that this desire
might well simply solve vaccine hesitancy that has vexed public health officials all over the world [1]. This has not been the case with substantial fractions of polled populations averring that they would not take a vaccine even if it passed phase 3 trials and was accepted and approved by the relevant regulators [6,15]. The determinants of such hesitancy are composite and vary by country and temporality [6]. Confidence, complacency and convenience are perceived as key aspects for vaccine acceptance [6]. Truly, public health must extend beyond providing services and should additionally tailor polices to counteract fake news and inculcate confidence in said policies [1]. This should include vigorous planning so as to ensure the readiness of both the general public and the medical/health community for a COVID-19 vaccine [14].

5. Conclusion

Novel COVID-19 vaccine uptake in General Practitioners/Family Doctors is slightly lower than annual influenza vaccination uptake of doctors in general. GPs are instrumental in vaccination programs and it is crucial to commence an information campaign as soon as possible with regard to the efficacy and safety of the upcoming vaccine to this group of medical professionals [5]. They will also almost certainly be utilised in the eventual vaccine drive when a COVID-19 vaccine actually becomes available, and comprehensive knowledge with regard to the vaccine will empower them to deliver the message to the general public. This can be done by involving them in the vaccination program in similar fashion to the annual modus operandi vis-à-vis influenza vaccination. Particular focus should be given to the GP Trainees who, as youths, can be role models for other youths, especially the vulnerable. Additionally an intense informational campaign targeting all healthcare workers (including all doctors) should be embarked upon to promote the yearly influenza vaccination.

Declaration of competing interest

The authors have no conflict of interest to declare.

References

[1] E.A. Harrison, J.W. Wu, Vaccine confidence in the time of COVID-19, Eur J Epidemiol. 35 (4) (2020 Apr) 325–330, https://doi.org/10.1007/s10654-020-00634-5. Epub 2020 Apr 22. PMID: 32318915; PMCID: PMC7174145.

[2] L.B. Stolle, R. Nalamasu, J.V. Pergolizzi Jr., G. Varrassi, P. Magnusson, J. LeQuang, F. Breve, NEMA Research Group, Fact vs Fallacy: the anti-vaccine discussion reloaded, Adv Ther. (2020 Sep 23), https://doi.org/10.1007/s12126-020-01502-y. Epub ahead of print, 32965654.

[3] W. Feleszko, P. Lewalis, A. Czarnecki, P. Waszkiewicz, Flattening the curve of COVID-19 vaccine rejection—a global overview, Available at SSRN, https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3631972, 2020 Jun 20.

[4] F. Collange, P. Verger, O. Launay, C. Pulcini, Knowledge, attitudes, beliefs and behaviors of general practitioners/family physicians toward their own vaccination: a systematic review, Hum Vaccin Immunother. 12 (5) (2016 May 3) 1282–1292, https://doi.org/10.1080/21640515.2015.1138024. Epub 2016 Apr 14. PMID: 27078723; PMCID: PMC4963063.

[5] P. Stefanof, T. Sobierajski, H. Bulinska-Stangerek, E. Augustynowicz, Exploring factors improving support for vaccinations among Polish primary care physicians, PLoS One 15 (5) (2020 May 1) e0232722, https://doi.org/10.1371/journal.pone.0232722. PMID: 32357190; PMCID: PMC7194393.

[6] P. Verger, L. Fressard, P. Collange, A. Gautier, C. Jestin, O. Launay, J. Raudé, C. Pulcini, P. Peretti-Watel, Vaccine hesitancy among general practitioners and its determinants during controversies: a national cross-sectional survey in France, EBioMedicine 2 (8) (2015 Jun 23) 891–897, https://doi.org/10.1016/j.ebiom.2015.06.018. PMID: 26425964; PMCID: PMC4563133.

[7] WHO, UNICEF, Malta: WHO and UNICEF estimates of immunization coverage: 2016 revision. shorturl.at/qtxKZ.

[8] V.M. Konala, S. Adapa, S. Naramala, A. Chenna, S. Lamichhane, P.R. Garlapati, M. Balla, V. Gayan, A case series of patients coinfected with influenza and COVID-19, J Infectig Med High Impact Case Rep. 8 (2020 Jan-Dec), 23247096209934674, https://doi.org/10.1177/23247096209934674. PMID: 32522057; PMCID: PMC7290261.

[9] V. Grech, C. Gueci, S. Agius, S.A. Montalto, Influenza vaccination survey in Maltese healthcare workers in the COVID-19 era, Malta Medical School Gazette. 4 (1) (2020 Aug 13) 17–24.

[10] M.J. Pedersen, N. Favero, Social distancing during the COVID-19 pandemic: who are the present and future non-compliers? Public Adm Rev. (2020 May 22) https://doi.org/10.1111/puar.13240. Epub ahead of print. PMID: 32836442; PMCID: PMC7280647.

[11] F. Zhou, T. Yu, R. Du, G. Fan, Y. Liu, Z. Liu, J. Xiang, Y. Wang, B. Song, X. Gu, L. Guan, Y. Wei, H. Li, X. Wu, J. Xu, S. Tu, Y. Zhang, H. Chen, B. Cao, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet. 395 (10229) (2020 Mar 28) 1054–1062, https://doi.org/10.1016/S0140-6736(20)30566-3 (Epub 2020 Mar 11).

[12] J. McAteer, I. Ylidiirm, A. Chahrourdi, The VACCINES act: deciphering vaccine hesitancy in the time of COVID-19, Clin Infect Dis. 71 (15) (2020 Jul 28) 703–705, https://doi.org/10.1093/cid/ciaa433. PMID: 32282038; PMCID: PMC7184475.

[13] S. Sanche, Y.T. Lin, C. Xu, E. Romero-Severson, N. Hengartner, R. Ke, High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2, Emerg Infect Dis. 26 (7) (2020 Jul) 1470–1477, https://doi.org/10.3201/eid2607.200282. Epub 2020 Jun 21. PMID: 32255761; PMCID: PMC7325562.

[14] P. Verger, E. Dubé, Restoring confidence in vaccines in the COVID-19 era, Expert Rev Vaccines. (2020 Sep 17), https://doi.org/10.1080/14760854.2020.1825945. Epub ahead of print, 32940574.

[15] S. Schaffer DeRoo, N.J. Pudalov, L.Y. Fu, Planning for a COVID-19 vaccination program, JAMA. 323 (24) (2020 Jun 23) 2458–2459, https://doi.org/10.1001/jama.2020.8711. 32421155.